{"id":"mesalazine-asacol","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-8","effect":"Nausea"},{"rate":"2-5","effect":"Rash"},{"rate":"<1","effect":"Nephrotoxicity (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Mesalazine (5-aminosalicylic acid) acts locally in the gastrointestinal tract to suppress inflammatory mediators and reduce immune cell activation. It works primarily by inhibiting nuclear factor-kappa B (NF-κB) signaling and reducing production of pro-inflammatory cytokines, thereby decreasing mucosal inflammation in inflammatory bowel disease.","oneSentence":"Mesalazine is an anti-inflammatory agent that reduces inflammation in the colon by inhibiting prostaglandin and leukotriene production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:52.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ulcerative colitis (induction and maintenance of remission)"},{"name":"Crohn's disease (colonic involvement)"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT00840203","phase":"PHASE1","title":"Mesalamine 4 gm/60 mL Rectal Enema","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT04969679","phase":"PHASE4","title":"Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment.","status":"COMPLETED","sponsor":"Kangbuk Samsung Hospital","startDate":"2018-03-16","conditions":"Ulcerative Colitis","enrollment":134},{"nctId":"NCT01469637","phase":"PHASE1","title":"Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-11-07","conditions":"Healthy","enrollment":44},{"nctId":"NCT01418365","phase":"PHASE1","title":"Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-08-22","conditions":"Healthy","enrollment":30},{"nctId":"NCT01402947","phase":"PHASE1","title":"Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-07-25","conditions":"Healthy","enrollment":30},{"nctId":"NCT01442688","phase":"PHASE1","title":"Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-07","conditions":"Healthy","enrollment":62},{"nctId":"NCT03689673","phase":"","title":"Study of the Effectiveness of ETIASA® (Sustained Release 5-Aminosalicylate) in Maintenance Treatment of Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Ipsen","startDate":"2013-04-24","conditions":"Ulcerative Colitis","enrollment":607},{"nctId":"NCT03399903","phase":"PHASE1, PHASE2","title":"Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection","status":"COMPLETED","sponsor":"AIDS Healthcare Foundation","startDate":"2017-05-01","conditions":"HIV-1-infection, Gut Inflammation","enrollment":47},{"nctId":"NCT00708656","phase":"PHASE3","title":"The Colitis Once Daily Asacol Study","status":"COMPLETED","sponsor":"Cardiff and Vale University Health Board","startDate":"2006-10","conditions":"Ulcerative Colitis","enrollment":213},{"nctId":"NCT03415711","phase":"NA","title":"PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis","status":"TERMINATED","sponsor":"VSL Pharmaceuticals","startDate":"2017-04-28","conditions":"Ulcerative Colitis","enrollment":14},{"nctId":"NCT00679432","phase":"PHASE3","title":"(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-06","conditions":"Ulcerative Colitis","enrollment":510},{"nctId":"NCT00408174","phase":"PHASE3","title":"Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2006-05","conditions":"Inflammatory Bowel Disease, Ulcerative Colitis","enrollment":400},{"nctId":"NCT01532648","phase":"PHASE3","title":"Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2012-01-27","conditions":"Ulcerative Colitis","enrollment":510},{"nctId":"NCT01016262","phase":"PHASE3","title":"Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2009-11-30","conditions":"Proctitis, Ulcerative","enrollment":119},{"nctId":"NCT02368743","phase":"","title":"QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2015-12","conditions":"Distal Ulcerative Colitis","enrollment":117},{"nctId":"NCT02368717","phase":"PHASE3","title":"An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2015-03","conditions":"Ulcerative Colitis","enrollment":281},{"nctId":"NCT01172444","phase":"PHASE3","title":"Clinical Trial With Mesalamine 1g Suppositories","status":"TERMINATED","sponsor":"Sandoz","startDate":"2010-06","conditions":"Proctitis","enrollment":158},{"nctId":"NCT00603733","phase":"PHASE3","title":"Canadian Active & Maintenance Modified Pentasa Study","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2007-10","conditions":"Active Ulcerative Colitis, Remission of Ulcerative Colitis","enrollment":288},{"nctId":"NCT01517607","phase":"","title":"Mesalazine (PENTASA®) in Ulcerative Colitis","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2012-02","conditions":"Ulcerative Colitis","enrollment":506},{"nctId":"NCT01586533","phase":"PHASE2","title":"Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis","status":"UNKNOWN","sponsor":"Altheus Therapeutics, Inc.","startDate":"2012-06","conditions":"Ulcerative Colitis, Left-sided Ulcerative Colitis, Distal Ulcerative Colitis","enrollment":120},{"nctId":"NCT01517594","phase":"","title":"Tolerability of Pentasa Sachet in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2011-10","conditions":"Ulcerative Colitis","enrollment":568},{"nctId":"NCT00505778","phase":"PHASE3","title":"A Comparison of Once a Day Dose Compared to 2 Doses/Day","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2007-07","conditions":"Ulcerative Colitis","enrollment":1027},{"nctId":"NCT00554099","phase":"PHASE2","title":"Asacol Acute Diverticulitis(DIVA)Study","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2007-11","conditions":"Diverticulitis","enrollment":117},{"nctId":"NCT01257399","phase":"PHASE3","title":"Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase","status":"COMPLETED","sponsor":"Tillotts Pharma AG","startDate":"2010-11","conditions":"Ulcerative Colitis in Remission","enrollment":251},{"nctId":"NCT01257386","phase":"PHASE3","title":"Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Tillotts Pharma AG","startDate":"2010-11","conditions":"Active Ulcerative Colitis","enrollment":251},{"nctId":"NCT00663247","phase":"NA","title":"Mechanistic Randomized Controlled Trial (RCT) of Mesalazine in Symptomatic Diverticular Disease","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2008-04","conditions":"Diverticulosis, Colonic","enrollment":40},{"nctId":"NCT01004185","phase":"PHASE3","title":"Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis","status":"TERMINATED","sponsor":"Warner Chilcott","startDate":"2009-10","conditions":"Ulcerative Colitis","enrollment":39},{"nctId":"NCT00713310","phase":"PHASE3","title":"Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2008-12","conditions":"Ulcerative Colitis","enrollment":83},{"nctId":"NCT00225810","phase":"PHASE4","title":"A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2005-10","conditions":"Crohn's Disease","enrollment":50},{"nctId":"NCT01045018","phase":"PHASE3","title":"A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis","status":"COMPLETED","sponsor":"EMET Pharmaceuticals, LLC","startDate":"2008-01","conditions":"Mild to Moderate Ulcerative Colitis","enrollment":""},{"nctId":"NCT00092508","phase":"PHASE3","title":"CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-05","conditions":"Ulcerative Colitis","enrollment":1725}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mesalazine","Asacol"],"phase":"phase_3","status":"active","brandName":"mesalazine (Asacol®)","genericName":"mesalazine (Asacol®)","companyName":"Cardiff and Vale University Health Board","companyId":"cardiff-and-vale-university-health-board","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mesalazine (Asacol) is a small molecule inhibitor of the enzyme arachidonate 5-lipoxygenase, classified as an INHIBITOR. It is used to treat conditions such as ulcerative colitis, as indicated by clinical trials on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}